关注
CHRISTOPHER VAN DYCK
CHRISTOPHER VAN DYCK
Professor of Psychiatry, Neurology, and Neuroscience, Yale School of Medicine
在 yale.edu 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Clarifying confusion: the confusion assessment method: a new method for detection of delirium
SK Inouye, CH van Dyck, CA Alessi, S Balkin, AP Siegal, RI Horwitz
Annals of internal medicine 113 (12), 941-948, 1990
65271990
Lecanemab in early Alzheimer’s disease
CH Van Dyck, CJ Swanson, P Aisen, RJ Bateman, C Chen, M Gee, ...
New England Journal of Medicine 388 (1), 9-21, 2023
29392023
Vitamin E and donepezil for the treatment of mild cognitive impairment
RC Petersen, RG Thomas, M Grundman, D Bennett, R Doody, S Ferris, ...
New England Journal of Medicine 352 (23), 2379-2388, 2005
24952005
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.
M Laruelle, A Abi-Dargham, CH Van Dyck, R Gil, CD D'Souza, J Erdos, ...
Proceedings of the National Academy of Sciences 93 (17), 9235-9240, 1996
16551996
Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial
RA Mulnard, CW Cotman, C Kawas, CH Van Dyck, M Sano, R Doody, ...
Jama 283 (8), 1007-1015, 2000
13272000
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials
M Grundman, RC Petersen, SH Ferris, RG Thomas, PS Aisen, DA Bennett, ...
Archives of neurology 61 (1), 59-66, 2004
12592004
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort
A Abi-Dargham, R Gil, J Krystal, RM Baldwin, JP Seibyl, M Bowers, ...
American journal of psychiatry 155 (6), 761-767, 1998
11421998
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
S Salloway, R Sperling, S Gilman, NC Fox, K Blennow, M Raskind, ...
Neurology 73 (24), 2061-2070, 2009
9262009
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial
JF Quinn, R Raman, RG Thomas, K Yurko-Mauro, EB Nelson, C Van Dyck, ...
Jama 304 (17), 1903-1911, 2010
9182010
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
RS Turner, RG Thomas, S Craft, CH Van Dyck, J Mintzer, BA Reynolds, ...
Neurology 85 (16), 1383-1391, 2015
6872015
High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial
PS Aisen, LS Schneider, M Sano, R Diaz-Arrastia, CH Van Dyck, ...
Jama 300 (15), 1774-1783, 2008
6682008
Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl) tropane and single photon emission computed tomography
RT Malison, LH Price, R Berman, CH van Dyck, GH Pelton, L Carpenter, ...
Biological psychiatry 44 (11), 1090-1098, 1998
6431998
Anti-amyloid-β monoclonal antibodies for Alzheimer’s disease: pitfalls and promise
CH Van Dyck
Biological psychiatry 83 (4), 311-319, 2018
6002018
Randomized trial of verubecestat for prodromal Alzheimer’s disease
MF Egan, J Kost, T Voss, Y Mukai, PS Aisen, JL Cummings, PN Tariot, ...
New England Journal of Medicine 380 (15), 1408-1420, 2019
5562019
[sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease
KL Marek, JP Seibyl, SS Zoghbi, Y Zea-Ponce, RM Baldwin, B Fussell, ...
Neurology 46 (1), 231-237, 1996
4621996
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease
V Coric, CH Van Dyck, S Salloway, N Andreasen, M Brody, RW Richter, ...
Archives of neurology 69 (11), 1430-1440, 2012
4442012
SPECT imaging of striatal dopamine release after amphetamine challenge
M Laruelle, A Abi-Dargham, CH van Dyck, W Rosenblatt, Y Zea-Ponce, ...
Journal of Nuclear Medicine 36 (7), 1182-1190, 1995
4351995
[123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression
K Marek, R Innis, C Van Dyck, B Fussell, M Early, S Eberly, D Oakes, ...
Neurology 57 (11), 2089-2094, 2001
4282001
Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging
MK Chen, AP Mecca, M Naganawa, SJ Finnema, T Toyonaga, S Lin, ...
JAMA neurology 75 (10), 1215-1224, 2018
3912018
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
M Sano, KL Bell, D Galasko, JE Galvin, RG Thomas, CH Van Dyck, ...
Neurology 77 (6), 556-563, 2011
3812011
系统目前无法执行此操作,请稍后再试。
文章 1–20